drugset / Trial / NCT00050206

Olanzapine Versus Placebo in the Treatment of Mania in Adolescents With Bipolar I Disorder

NCT00050206 ↗

Phase 4 Completed 130 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine the efficacy (how well the drug works), safety, and any side effects of olanzapine compared to placebo in the treatment of mania in bipolar disorder in adolescents. Both the potential benefits and side effects of olanzapine will be evaluated throughout this trial.

Timeline

Start
2002-11
Primary completion
—
Completion
2005-05

Outcome

Met primary endpoint

paper The mean baseline-to-endpoint change in the Young Mania Rating Scale total score was significantly greater for patients receiving olanzapine relative to patients receiving placebo PMID 17898346 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Olanzapine Small molecule — —

Indications